1147 related articles for article (PubMed ID: 30566590)
1. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4).
Boku N; Ryu MH; Kato K; Chung HC; Minashi K; Lee KW; Cho H; Kang WK; Komatsu Y; Tsuda M; Yamaguchi K; Hara H; Fumita S; Azuma M; Chen LT; Kang YK
Ann Oncol; 2019 Feb; 30(2):250-258. PubMed ID: 30566590
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK; Chen LT; Ryu MH; Oh DY; Oh SC; Chung HC; Lee KW; Omori T; Shitara K; Sakuramoto S; Chung IJ; Yamaguchi K; Kato K; Sym SJ; Kadowaki S; Tsuji K; Chen JS; Bai LY; Oh SY; Choda Y; Yasui H; Takeuchi K; Hirashima Y; Hagihara S; Boku N
Lancet Oncol; 2022 Feb; 23(2):234-247. PubMed ID: 35030335
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial.
Jiang H; Zheng Y; Qian J; Mao C; Xu X; Li N; Xiao C; Wang H; Teng L; Zhou H; Wang S; Zhu D; Peng B; Shen L; Xu N
BMC Cancer; 2020 Aug; 20(1):760. PubMed ID: 32795349
[TBL] [Abstract][Full Text] [Related]
4. Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the first-line therapy: a single-arm, phase 2 study.
Jiang Z; Zhou A; Sun Y; Zhang W
BMC Cancer; 2022 Mar; 22(1):253. PubMed ID: 35264150
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
6. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
[TBL] [Abstract][Full Text] [Related]
7. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of S-1 plus oxaliplatin 130 mg/m
Kashiwada T; Shinozaki K; Ueno S; Kawanaka H; Uno F; Okita Y; Fukahori M; Matsushita H; Emi Y; Shimokawa M; Makiyama A; Saeki H; Oki E; Maehara Y; Mori M; Baba E;
Int J Clin Oncol; 2021 Feb; 26(2):345-354. PubMed ID: 33085058
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
12. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial).
Lee KW; Chung IJ; Ryu MH; Park YI; Nam BH; Oh HS; Lee KH; Han HS; Seo BG; Jo JC; Lee HR; Kim JW; Park SR; Cho SH; Kang YK;
Gastric Cancer; 2021 Jan; 24(1):156-167. PubMed ID: 32596783
[TBL] [Abstract][Full Text] [Related]
13. A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
Kim GM; Jeung HC; Rha SY; Kim HS; Jung I; Nam BH; Lee KH; Chung HC
Eur J Cancer; 2012 Mar; 48(4):518-26. PubMed ID: 22243774
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1 antibody HX008 combined with oxaliplatin plus capecitabine for advanced gastric or esophagogastric junction cancer: a multicenter, single-arm, open-label, phase Ib trial.
Xu J; Xu N; Bai Y; Liu R; Mao C; Sui H; Wang X; Jiang Q; Dou Y
Oncoimmunology; 2020 Dec; 10(1):1864908. PubMed ID: 33457083
[TBL] [Abstract][Full Text] [Related]
15. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.
Janjigian YY; Shitara K; Moehler M; Garrido M; Salman P; Shen L; Wyrwicz L; Yamaguchi K; Skoczylas T; Campos Bragagnoli A; Liu T; Schenker M; Yanez P; Tehfe M; Kowalyszyn R; Karamouzis MV; Bruges R; Zander T; Pazo-Cid R; Hitre E; Feeney K; Cleary JM; Poulart V; Cullen D; Lei M; Xiao H; Kondo K; Li M; Ajani JA
Lancet; 2021 Jul; 398(10294):27-40. PubMed ID: 34102137
[TBL] [Abstract][Full Text] [Related]
16. A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Brell JM; Krishnamurthi SS; Javle M; Saltzman J; Wollner I; Pelley R; Dowlati A; Kantharaj BN; Schluchter MD; Rath L; Ivy SP; Remick SC
Cancer Chemother Pharmacol; 2009 Apr; 63(5):851-7. PubMed ID: 18670776
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II trial of pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously untreated patients with advanced gastric cancer.
Kim ST; Lee J; Lee SJ; Park SH; Jung SH; Park YS; Lim HY; Kang WK; Park JO
Oncotarget; 2016 Apr; 7(17):24088-96. PubMed ID: 27003363
[TBL] [Abstract][Full Text] [Related]
18. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
Hecht JR; Bang YJ; Qin SK; Chung HC; Xu JM; Park JO; Jeziorski K; Shparyk Y; Hoff PM; Sobrero A; Salman P; Li J; Protsenko SA; Wainberg ZA; Buyse M; Afenjar K; Houé V; Garcia A; Kaneko T; Huang Y; Khan-Wasti S; Santillana S; Press MF; Slamon D
J Clin Oncol; 2016 Feb; 34(5):443-51. PubMed ID: 26628478
[TBL] [Abstract][Full Text] [Related]
19. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Koizumi W; Takiuchi H; Yamada Y; Boku N; Fuse N; Muro K; Komatsu Y; Tsuburaya A
Ann Oncol; 2010 May; 21(5):1001-5. PubMed ID: 19875759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
